Phibro Animal Health Corporation (NASDAQ:PAHC) Receives $42.50 Average Price Target from Analysts

Phibro Animal Health Corporation (NASDAQ:PAHC) has been assigned an average rating of “Hold” from the five research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $42.50.

PAHC has been the subject of several recent analyst reports. Weiss Ratings downgraded Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Citigroup decreased their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Finally, Wall Street Zen cut shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th.

Phibro Animal Health Stock Performance

Shares of PAHC opened at $33.26 on Friday. Phibro Animal Health has a 12 month low of $25.58 and a 12 month high of $60.08. The stock has a fifty day moving average price of $36.91 and a 200-day moving average price of $43.86. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97. The firm has a market cap of $1.35 billion, a PE ratio of 14.27, a P/E/G ratio of 0.45 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The firm had revenue of $383.54 million for the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Equities research analysts predict that Phibro Animal Health will post 3.08 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd were paid a dividend of $0.12 per share. The ex-dividend date was Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 1.4%. Phibro Animal Health’s dividend payout ratio is presently 20.60%.

Insider Activity

In other news, CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total transaction of $392,832.00. Following the completion of the sale, the chief executive officer directly owned 67,720 shares in the company, valued at approximately $3,778,776. The trade was a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 46,768 shares of company stock valued at $2,560,222 over the last three months. Company insiders own 50.13% of the company’s stock.

Hedge Funds Weigh In On Phibro Animal Health

Hedge funds have recently made changes to their positions in the company. Cetera Investment Advisers increased its position in shares of Phibro Animal Health by 2.7% in the first quarter. Cetera Investment Advisers now owns 10,997 shares of the company’s stock valued at $608,000 after buying an additional 293 shares in the last quarter. 1620 Investment Advisors Inc. lifted its position in shares of Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after buying an additional 295 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in shares of Phibro Animal Health by 3.4% during the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after buying an additional 338 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Phibro Animal Health by 2.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after acquiring an additional 363 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after acquiring an additional 386 shares during the period. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.